TABLE 1.
The class and list of Prostaglandin Analogs.
| Mode of action | Mechanism | Drug | IOP reduction | Current market status | Usage, dosage | Side effects (ocular) |
|---|---|---|---|---|---|---|
| F2 receptor agonists | Increasing uveoscleral outflow | Latanoprost | 25–33% | On the market | Once daily | Conjunctival hyperaemia; Eyelash lengthening; Increased periocular and iris pigmentation; Prostaglandin-associated; Periorbitopathy |
| Bimatoprost | ||||||
| Travoprost | ||||||
| Tafluprost | ||||||
| E2-EP2 receptor dual agonists | Increasing uveoscleral outflow | Omidenepag isopropyl | 10–15% | On the market | Once daily | |
| Aganepag isopropyl | 25–33% | Phase II | ||||
| AGN-210669 | — | |||||
| E2-EP3-F2-receptor three agonists | Increasing uveoscleral outflow | Sepetaprost | 27–30% | Phase II | Once daily | |
| Nitric-oxide donating F2 receptor agonists | Increasing uveoscleral outflow; Increasing trabecular outflow | Latanoprostene bunod NCX 470 | 32–34% | On the market Phase III | Once daily |